Go Back

ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers

11.15.2022

– Affini-T will leverage ElevateBio BaseCamp’s LentiPeakTM lentiviral vector technology platform and cell product manufacturing capabilities to progress its investigational T cell therapies targeting core oncogenic drivers into clinical development –

Waltham, Mass., and Watertown, Mass., – November 15, 2022 – ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, and Affini-T Therapeutics, a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced a partnership to advance Affini-T’s engineered TCR-T therapies focused on KRAS (Kirsten rat sarcoma viral oncogene homolog), one of the most prevalent oncogenic driver mutations in solid tumor cancers. Affini-T will leverage ElevateBio BaseCamp’s LentiPeak^TM lentiviral vector technology platform and cell therapy production capabilities to advance its investigational oncogenic driver programs into clinical development. ElevateBio BaseCamp is a purpose-built viral vector and cell therapy center of excellence with end-to-end process development and current Good Manufacturing Practice (cGMP) manufacturing capabilities for research, clinical and commercial cell and gene therapies, and regenerative medicines.

“Affini-T is pioneering novel T cell therapy approaches to treat solid tumor cancers by striking at the core of tumor biology, which entails leveraging the most advanced tools and techniques in cell engineering,” said Kim Nguyen, Ph.D., Chief Technical Officer, Affini-T Therapeutics. “Deep expertise in autologous cellular therapies manufacturing and analytics combined with its scalable platform for suspension-based lentiviral production, make ElevateBio an ideal partner as we progress our oncogenic driver programs into the clinic and work to deliver transformative therapies to patients and their families.”

“We are pleased that our LentiPeak platform and cell therapy expertise can enable innovative developers like Affini-T to further accelerate their pipeline and look forward to working together so that we can bring forth these important therapies for difficult to treat solid tumors,” said David Hallal, Chairman and Chief Executive Officer of ElevateBio. “At ElevateBio, we’ve combined multiple next-generation technology platforms with industry-leading expertise to transform the current cell and gene therapy development paradigm and provide our partners with a strategic advantage in the development of their therapies, and ultimately improve the speed of novel therapies to patients.”

Affini-T’s proprietary platform is designed to select and engineer the right immune cells to orchestrate a durable and coordinated immune response within the immunosuppressive tumor microenvironment. The company is pioneering engineered T cell therapies with cutting-edge synthetic biology and gene editing enhancements to target oncogenic driver mutations at the core of tumor biology. Its engineered cell therapies are designed to overcome the immunosuppressive tumor microenvironment, enhancing T cell function to increase durability, build persistent responses, and augment tumor infiltration. Affini-T’s investigational cell therapies have the potential to offer new treatment options for patients affected by cancer with mutant variants of KRAS, which account for up to 30% of all cancers and are particularly frequent in cancers with high mortality rates, including lung cancer, colorectal cancer, and pancreatic cancer.

About ElevateBio:

ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, ElevateBio BaseCamp in Waltham, MA, is a purpose-built facility offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities. It was designed to support diverse cell and gene therapy products, including autologous, allogeneic, and regenerative medicine cell products and viral vector manufacturing capabilities.

Through BaseCamp and its enabling technologies, ElevateBio is focused on growing its collaborations with industry partners while also developing its own portfolio of cellular and genetic medicines. ElevateBio’s team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.

For more information, visit us at www.elevate.bio, or follow ElevateBio on LinkedIn and Twitter, or Instagram.

About Affini-T Therapeutics

Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on LinkedIn and Twitter.

Contacts

ElevateBio Company Contact:
Catherine Hu
chu@elevate.bio

ElevateBio Media Contact:
Courtney Heath
ScientPR
Courtney@scientpr.com

Affini-T Media Contact:
Danielle Cantey
Evoke Canale
Danielle.Cantey@evokegroup.com
619-826-4657

Affini-T Investor Contact
Ailsa Dalgliesh, PhD
ailsa@affinittx.com